Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis
Introduction The relative efficacy and safety of once-daily oral semaglutide vs. injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in subjects with type 2 diabetes (T2D) inadequately controlled on basal insulin were assessed using network meta-analysis (NMA). Methods A systematic literature review (SLR) was performed to identify randomised controlled trials of GLP-1 RAs in this population. Data at 26 ± 4 weeks were extracted for efficacy and safety outcomes feasible for the NMA: change from baseline in glycated haemoglobin ($ HbA_{1c} $), weight and blood pressure; $ HbA_{1c} $ target levels (< 7.0% and ≤ 6.5%); composite endpoint; incidence of nausea, vomiting or diarrhoea. Comparators of interest were all licensed doses of dulaglutide, exenatide, liraglutide, lixisenatide and once-weekly injectable semaglutide. Results The NMA included seven trials. Once-daily oral semaglutide 14 mg was associated with significantly greater $ HbA_{1c} $ reductions vs. most comparators (treatment differences: − 0.42 to − 1.32%); differences vs. once-weekly injectable semaglutide (0.5 mg and 1 mg doses) were not statistically significant. Once-daily oral semaglutide 14 mg was associated with significantly greater weight reductions vs. exenatide 2 mg and lixisenatide 20 μg (− 2.21 and − 2.39 kg respectively); non-statistically significant weight reductions in favour of once-daily oral semaglutide 14 mg were observed vs. all other comparators except once-weekly injectable semaglutide 1 mg. Similar trends were observed for the proportion of subjects achieving $ HbA_{1c} $ < 7.0% and ≤ 6.5% and the composite endpoint. Once-daily oral semaglutide 14 mg was associated with similar odds of experiencing nausea, vomiting or diarrhoea vs. all comparators. Conclusion Once-daily oral semaglutide 14 mg, as an add-on to basal insulin, is an efficacious treatment for reducing $ HbA_{1c} $ and weight and meeting glycaemic targets at 26 ± 4 weeks. Once-daily oral semaglutide 14 mg also offers the option of an oral treatment with similar or better efficacy and similar tolerability vs. most injectable GLP-1 RAs..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Diabetes therapy - 12(2021), 5 vom: 16. März, Seite 1325-1339 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chubb, Barrie [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Basal insulin |
---|
doi: |
10.1007/s13300-021-01034-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR043953328 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR043953328 | ||
003 | DE-627 | ||
005 | 20230519185034.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210506s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s13300-021-01034-w |2 doi | |
035 | |a (DE-627)SPR043953328 | ||
035 | |a (DE-599)SPRs13300-021-01034-w-e | ||
035 | |a (SPR)s13300-021-01034-w-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Chubb, Barrie |e verfasserin |4 aut | |
245 | 1 | 0 | |a Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Introduction The relative efficacy and safety of once-daily oral semaglutide vs. injectable glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in subjects with type 2 diabetes (T2D) inadequately controlled on basal insulin were assessed using network meta-analysis (NMA). Methods A systematic literature review (SLR) was performed to identify randomised controlled trials of GLP-1 RAs in this population. Data at 26 ± 4 weeks were extracted for efficacy and safety outcomes feasible for the NMA: change from baseline in glycated haemoglobin ($ HbA_{1c} $), weight and blood pressure; $ HbA_{1c} $ target levels (< 7.0% and ≤ 6.5%); composite endpoint; incidence of nausea, vomiting or diarrhoea. Comparators of interest were all licensed doses of dulaglutide, exenatide, liraglutide, lixisenatide and once-weekly injectable semaglutide. Results The NMA included seven trials. Once-daily oral semaglutide 14 mg was associated with significantly greater $ HbA_{1c} $ reductions vs. most comparators (treatment differences: − 0.42 to − 1.32%); differences vs. once-weekly injectable semaglutide (0.5 mg and 1 mg doses) were not statistically significant. Once-daily oral semaglutide 14 mg was associated with significantly greater weight reductions vs. exenatide 2 mg and lixisenatide 20 μg (− 2.21 and − 2.39 kg respectively); non-statistically significant weight reductions in favour of once-daily oral semaglutide 14 mg were observed vs. all other comparators except once-weekly injectable semaglutide 1 mg. Similar trends were observed for the proportion of subjects achieving $ HbA_{1c} $ < 7.0% and ≤ 6.5% and the composite endpoint. Once-daily oral semaglutide 14 mg was associated with similar odds of experiencing nausea, vomiting or diarrhoea vs. all comparators. Conclusion Once-daily oral semaglutide 14 mg, as an add-on to basal insulin, is an efficacious treatment for reducing $ HbA_{1c} $ and weight and meeting glycaemic targets at 26 ± 4 weeks. Once-daily oral semaglutide 14 mg also offers the option of an oral treatment with similar or better efficacy and similar tolerability vs. most injectable GLP-1 RAs. | ||
650 | 4 | |a Basal insulin |7 (dpeaa)DE-He213 | |
650 | 4 | |a GLP-1 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Glycaemic control |7 (dpeaa)DE-He213 | |
650 | 4 | |a Network meta-analysis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Semaglutide |7 (dpeaa)DE-He213 | |
650 | 4 | |a Systematic review |7 (dpeaa)DE-He213 | |
650 | 4 | |a Type 2 diabetes |7 (dpeaa)DE-He213 | |
700 | 1 | |a Gupta, Palvi |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Jatin |e verfasserin |4 aut | |
700 | 1 | |a Nuhoho, Solomon |e verfasserin |4 aut | |
700 | 1 | |a Kallenbach, Klaus |e verfasserin |4 aut | |
700 | 1 | |a Orme, Michelle |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diabetes therapy |d New York, NY [u.a.] : Springer Healthcare Communications, 2010 |g 12(2021), 5 vom: 16. März, Seite 1325-1339 |w (DE-627)SPR031248403 |w (DE-600)2566702-6 |x 1869-6961 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2021 |g number:5 |g day:16 |g month:03 |g pages:1325-1339 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13300-021-01034-w |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 12 |j 2021 |e 5 |b 16 |c 03 |h 1325-1339 |